Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly has warned of high levels of an impurity in certain compounded versions of its blockbuster glucagon-like peptide-1 ...

Eli Lilly's growth rate has accelerated significantly in recent years due to its GLP-1 drugs. The stock, however, trades at more than 40 times its trailing earnings. Eli Lilly (NYSE: LLY) has been an ...

U.S. health officials have approved a new weight-loss pill from Eli Lilly. The Food and Drug Administration's decision ...

WASHINGTON, March 12 (Reuters) - Compounded weight-loss drugs that contain vitamin B12 and the ‌main ingredient in Eli Lilly's (LLY.N), opens new tab Zepbound could present health risks to consumers ...

Several pharmaceutical companies have recently posted encouraging clinical data for their weight-loss candidates. However, most of these won't be approved soon, and Eli Lilly has strong programs of ...

This is read by an automated voice. Please report any issues or inconsistencies here. “Southern Hospitality” star Grace Lilly was arrested Tuesday in South Carolina on suspicion of drug possession ...

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...

Eli Lilly is infusing $3 billion into its manufacturing operations in China, pledging to set up local production and supply for oral solid drugs as it works on building out capacity for its ...

Southern Hospitality star Grace Lilly was arrested on a drug possession charge on Tuesday, March 10. Online court records viewed by Us Weekly show that Lilly, 27, was booked in Charleston County, ...

Hims & Hers Health (HIMS) has made a major change in its PR function with the hiring of Kathryn Beiser, who has served Lilly (LLY) as the weight loss drugmaker’s chief communications officer for five ...

Eli Lilly (LLY) is down to the $937 area as investors await an April FDA decision on its oral obesity pill, orforglipron. Moreover, shares of Eli Lilly rival Novo Nordisk (NVO) are down 25% year to ...

Eli Lilly is building an insurmountable lead in GLP-1 drugs through superior clinical efficacy of tirzepatide, direct-to-employer distribution that bypasses pharmacy benefit managers, and a ...